Evonik Industries AG
F:EVKA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Evonik Industries AG
F:EVKA
|
DE |
Earnings Calls
Last Earnings Call
Strong quarter: Evonik said Q2 was the best quarterly result in 4 years, with adjusted EBITDA up 24% year over year to EUR 630 million and above expectations.
Outlook raised: Management reiterated the upgraded full-year outlook that lifted the midpoint by EUR 250 million and said Q3 should be at least as strong as Q2, with some normalization expected in Q4.
Methionine strength: Methionine remained a major earnings driver, with management saying Q3 should be the best methionine quarter of the year and that the business should outperform most expectations in 2026.
Cost cuts expanded: Evonik extended its Tailor-made restructuring program and now plans to reduce about 3,200 more positions between 2027 and 2029, on top of earlier reductions.
Cash improved: Cash generation improved significantly, helping support the full-year target of around 40% cash conversion and reducing pressure on net financial debt seasonally.
Capital use: Management said the new dividend policy starts in May 2027 and that a share buyback is not currently on the agenda.